Lonza Appoints Richard Ridinger as New CEO
News Apr 05, 2012
At a meeting on 2 April 2012, the Board of Directors of Lonza elected Mr. Richard Ridinger as the new CEO of Lonza.
Mr. Ridinger will become CEO of Lonza effective 1 May. Rolf Soiron was acting CEO ad interim, since the end of January.
Richard Ridinger is 53 years old, a German national, and has extensive industrial leadership experience. “Richard Ridinger could be a person who grew up with Lonza”, said Rolf Soiron.
Soiron continues, “He is a chemical engineer who knows our industries, customers and products. With Richard Ridinger, we were not only able to attract a man of action and team player, but also a winning personality.”
Richard Ridinger has held numerous leadership functions at Henkel for 14 years and Cognis for 11 years.
Most recently, Mr. Ridinger was responsible for Care Chemicals, the largest sector at Cognis with approximately 3,000 employees.
During his tenure, sales increased by 60% to €1.75 billion over six years, as he successfully repositioned the business in the market.
Mr. Ridinger’s experience spans process development, production management, product- and marketing management of different product areas, leading global business units and finally the co-responsibility for leading a worldwide group of the specialty chemicals.
In working together with the private equity owners of Cognis, Richard Ridinger has proven his ability to achieve business excellence as well as to fulfill strategic and economical goals.
Following the takeover of Cognis by BASF at end of 2010, Richard Ridinger supported the integration of the company.
As CEO of Lonza, Mr. Ridinger has been mandated with strengthening Lonza’s market position in relevant markets, strengthening competitive capabilities, and productivity improvement in critical areas.
Productivity improvement includes project “Visp Challenge”, which is expected to contribute more than CHF 100 million over three years, and it also includes a review of group-wide structures.
The goal of these measures is a stepwise improvement of growth and return on capital.
At the 2 April meeting, the Board of Directors also appointed Mr. Marc Funk, Group General Counsel and Board Secretary, to become a member of the Management Committee.
Marc Funk joined Lonza in January 2009; prior he was associate general counsel at Merck Serono.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE